Radiopharm Theranostics (RDPTF) Cash & Equivalents (2023 - 2026)

Radiopharm Theranostics (RDPTF) has reported Cash & Equivalents for 4 consecutive years, with $29353.6 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 84.26% year-over-year to $29353.6 in Q2 2026; TTM through Jun 2026 was $29353.6, a 84.26% decrease from a year earlier, with the FY2026 full-year figure at $28104.1, down 99.9% from the prior year.
• Cash & Equivalents was $29353.6 for Q2 2026 at Radiopharm Theranostics, down from $186473.9 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $36.4 million in Q4 2024 and troughed at $29353.6 in Q2 2026.
• A 4-year average of $9.7 million and a median of $186473.9 in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 98.95% in 2024 and jumped 52.33% in 2025, its largest moves.
• Over 4 years, Cash & Equivalents stood at $11.7 million in 2023, then surged by 211.45% to $36.4 million in 2024, then sank by 99.49% to $186473.9 in 2025, then slumped by 84.26% to $29353.6 in 2026.
• The last three Cash & Equivalents figures came in at $29353.6 (Q2 2026), $186473.9 (Q2 2025), and $36.4 million (Q4 2024), per Business Quant data.